New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
07:02 EDTZSPHZS Pharma initiated with an Outperform at William Blair
William Blair believes management of hyperkalemia has the potential to become a significant market. The firm started shares of ZS Pharma with an Outperform rating and $75 price target.
News For ZSPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
07:26 EDTZSPHBMO Capital specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Maris, along with Dr. Kosiborod, Cardiologist, St. Luke's Mid-America Heart Institute discuss limitations of current standard of care and innovative new treatments for Hyperkalemia, including ZS Pharma’s ZS-9 and Relypsa’s Patiromer on an Analyst/Industry conference call to be held on April 27 at 11 am.
April 15, 2015
17:16 EDTZSPHZS Pharma's hyperkalemia candidate shows positive data in two publications
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use